4.7 Article

3-Hydrazinoisatin-based benzenesulfonamides as novel carbonic anhydrase inhibitors endowed with anticancer activity: Synthesis, in vitro biological evaluation and in silico insights

期刊

出版社

ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.111768

关键词

Anticancer; Benzenesulfonamides; Colony forming assay; Carbonic anhydrase inhibitors; Molecular dynamics

资金

  1. Czech Science Foundation [19-090865]
  2. European Regional Development Fund (Project ENOCH) [CZ.02.1.01/0.0/0,0/16_019/0000868]
  3. Palackji University in Olomouc [IGA_PrF_2019_013]

向作者/读者索取更多资源

Herein we describe the design and synthesis of two series of sulfonamides featuring N-unsubstituted (4a-c) or N-substituted (7a-o) isatin moieties (as tails) connected to benzenesulfonamide moiety via a hydrazine linker. All the prepared sulfonamides (4a-c and 7a-o) showed potent inhibitory activities toward transmembrane tumor-associated human (h) carbonic anhydrase (hCA, EC 4.2.1.1) isoforms, IX and XII with Ki range (8.3-65.4 nM) and (11.9-72.9 nM), respectively. Furthermore, six sulfonamides (7e, 7i, 7j, 7m, 7n and 7o) were assessed for their anti-proliferative activity, according to US-NCI protocol, toward a panel of sixty cancer cell lines. Compounds 7j and 7n were the most promising counterparts in this assay displaying broad spectrum anti-proliferative activity toward diverse cell lines. Also, sulfonamide 7n significantly inhibited clonogenicity of HCT-116 cells in a concentration dependent manner in the colony forming assay. Moreover, molecular modeling studies were performed to gain insights for the plausible binding interactions and affinities for the target isatin-based sulfonamides (4a-c and 7a-o) within hCA isoforms II and IX active sites. (C) 2019 Elsevier Masson SAS. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biochemistry & Molecular Biology

4-Cyanamidobenzenesulfonamide derivatives: a novel class of human and bacterial carbonic anhydrase inhibitors

Morteza Abdoli, Alessandro Bonardi, Claudiu T. Supuran, Raivis Zalubovskis

Summary: A one-pot two-step protocol was developed for the synthesis of novel 4-cyanamidobenzenesulfonamides, which showed effective inhibition towards both human and bacterial carbonic anhydrase enzymes.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)

Article Chemistry, Medicinal

4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments

Mahmoud A. Ragab, Wagdy M. Eldehna, Alessio Nocentini, Alessandro Bonardi, Hazem E. Okda, Bahaa Elgendy, Tarek S. Ibrahim, Mohammad M. Abd-Alhaseeb, Paola Gratteri, Claudiu T. Supuran, Ahmed A. Al-Karmalawy, Mohamed Elagawany

Summary: In the current medical era, the traditional single target inhibition paradigm of drug discovery is being replaced by the multi-target design concept. A novel series of 4-(5-amino-pyrazol-1-yl)benzenesulfonamide derivatives was designed and synthesized as potential multi-target anti-inflammatory agents. The compounds showed inhibitory activities against COX-2, 5-LOX, and carbonic anhydrase (CA) isoforms, suggesting their potential application in treating inflammatory diseases with a multi-target approach.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Novel thiazolone-benzenesulphonamide inhibitors of human and bacterial carbonic anhydrases

Morteza Abdoli, Viviana De Luca, Clemente Capasso, Claudiu T. T. Supuran, Raivis Zalubovskis

Summary: A library of novel thiazolone-benzenesulphonamides was synthesized and evaluated for their inhibitory activity against human cytosolic carbonic anhydrases and bacterial carbonic anhydrases. The prepared compounds 4a-4j showed low nanomolar range inhibition against all investigated hCAs. Compound 4d exhibited strong inhibition against bacterial MscCA beta with a K-I of 73.6 nM, much better than AAZ. The tested compounds showed medium inhibitory potency against StCA1 compared to the standard drug, while poorly inhibited StCA2.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)

Review Infectious Diseases

Carbonic Anhydrase Inhibitors as Novel Antibacterials in the Era of Antibiotic Resistance: Where Are We Now?

Alessio Nocentini, Clemente Capasso, Claudiu T. Supuran

Summary: Resistance to antibiotic treatment occurs when microorganisms resist clinically approved antibiotics. Medication repurposing/repositioning is a strategy that can help find new antibiotics. Among them, Zn2+ ion binders, such as sulfonamides and their bioisosteres, are considered promising compounds for obtaining novel antibacterials.

ANTIBIOTICS-BASEL (2023)

Article Medicine, Research & Experimental

Characterization of new highly selective pyrazolo[4,3-d]pyrimidine inhibitor of CDK7

Marketa Kovalova, Libor Havlicek, Stefan Djukic, Jana Skerlova, Miroslav Perina, Tomas Pospisil, Eva Reznickova, Pavlina Rezacova, Radek Jorda, Vladimir Krystof

Summary: Targeting cyclin-dependent kinase 7 (CDK7) with a new trisubstituted pyrazolo[4,3-d]pyrimidine derivative, LGR6768, inhibits CDK7 in the nanomolar range and shows favorable selectivity across the CDK family. LGR6768 affects cell cycle regulation and transcription by inhibiting the phosphorylation of cell cycle CDKs and the carboxy-terminal domain of RNA polymerase II. It limits leukemia cell proliferation and induces apoptosis through changes in protein and mRNA levels related to CDK7 inhibition.

BIOMEDICINE & PHARMACOTHERAPY (2023)

Review Chemistry, Medicinal

A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022)

Marketa Kovalova, Joseph Peter Baraka, Vaclav Mik, Radek Jorda, Lei Luo, Hao Shao, Vladimir Krystof

Summary: CDK7 is a protein kinase that regulates the cell cycle and mRNA transcription, and it has emerged as a potential drug target in oncology. Six promising drug candidates have been evaluated in early clinical trials. This review analyzes patents published from 2018 to 2022 and provides an overview of CDK7 inhibitors as anticancer drugs, including their chemical structures, biochemical profiles, and developmental stages.

EXPERT OPINION ON THERAPEUTIC PATENTS (2023)

Article Biochemistry & Molecular Biology

Antimicrobial and Antibiofilm Activities of Carvacrol, Amoxicillin and Salicylhydroxamic Acid Alone and in Combination vs. Helicobacter pylori: Towards a New Multi-Targeted Therapy

Valentina Puca, Gabriele Turacchio, Beatrice Marinacci, Claudiu T. Supuran, Clemente Capasso, Pamela Di Giovanni, Ilaria D'Agostino, Simone Carradori, Rossella Grande

Summary: The World Health Organization has identified Helicobacter pylori as a high-priority pathogen requiring updated antibacterial treatments. This study investigated the potential of combining a CA inhibitor, carvacrol (CAR), amoxicillin (AMX), and a urease inhibitor (SHA) to develop a multiple-targeted anti-H. pylori therapy. The combinations of these compounds showed strong inhibition of H. pylori growth and biofilm formation, with CAR-AMX and CAR-SHA combinations demonstrating additive effects and AMX-SHA combination showing indifferent effects.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

Development of novel anilinoquinazoline-based carboxylic acids as non-classical carbonic anhydrase IX and XII inhibitors

Zainab M. M. Elsayed, Hadia Almahli, Alessio Nocentini, Andrea Ammara, Claudiu T. T. Supuran, Wagdy M. M. Eldehna, Sahar M. M. Abou-Seri

Summary: In this study, a new series of non-classical CA inhibitors, 2-aryl-quinazolin-4-yl aminobenzoic acid derivatives, were designed and synthesized as potential anticancer candidates. The inhibitory activities of these compounds against different CA isoforms were evaluated, and selected compounds were further tested for their anti-proliferative activity against human cancer cell lines.

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2023)

Article Biochemistry & Molecular Biology

Inhibition Studies on Human and Mycobacterial Carbonic Anhydrases with N-((4-Sulfamoylphenyl)carbamothioyl) Amides

Morteza Abdoli, Alessandro Bonardi, Niccolo Paoletti, Ashok Aspatwar, Seppo Parkkila, Paola Gratteri, Claudiu T. Supuran, Raivis Zalubovskis

Summary: A library of structurally diverse N-((4-sulfamoylphenyl)carbamothioyl) amides was synthesized by selectively acylating 4-thioureidobenzenesulfonamide with various acyl chlorides. The inhibitory effects of these sulfonamides on human carbonic anhydrase (hCA) and bacterial beta-carbonic anhydrase from Mycobacterium tuberculosis (MtCA) were investigated in vitro and in silico. The compounds showed better inhibition against hCA I, hCA II, hCA VII, as well as MtCA1 and MtCA2, but poor inhibition against MtCA3.

MOLECULES (2023)

Article Chemistry, Medicinal

6-Aminocoumarin oxime-ether/sulfonamides as selective hCA IX and XII inhibitors: Synthesis, evaluation, and molecular dynamics studies

Shaik Mahammad Ghouse, Kareena Sinha, Alessandro Bonardi, Gaurav Pawar, Satyaveni Malasala, Srikanth Danaboina, Arifuddin Mohammed, Venkata M. Yaddanapudi, Claudiu T. Supuran, Srinivas Nanduri

Summary: Carbonic anhydrase isoforms IX and XII are highly expressed in hypoxic tumor cells and play a role in cancer onset and spread. Coumarin derivatives were found to selectively inhibit these isoforms, offering a promising strategy for anticancer therapy. This study identified 6-aminocoumarin sulfonamide and oxime ether derivatives as potent inhibitors of human carbonic anhydrase IX and XII. The results demonstrate the potential of these derivatives as selective inhibitors and provide a foundation for further development as anticancer agents.

ARCHIV DER PHARMAZIE (2023)

Article Chemistry, Medicinal

Antimalarial Agents Targeting Plasmodium falciparum Carbonic Anhydrase: Towards Artesunate Hybrid Compounds with Dual Mechanism of Action

Ilaria D'Agostino, Susi Zara, Simone Carradori, Viviana De Luca, Clemente Capasso, Clemens H. M. Kocken, Anne-Marie Zeeman, Andrea Angeli, Fabrizio Carta, Claudiu T. Supuran

Summary: The hybrid compounds synthesized in this study, which combine the Artesunate core with a sulfonamide moiety, showed high inhibition potency against the protozoan PfCA, while exhibiting low cytotoxic effects on human cells, indicating a wide therapeutic window.

CHEMMEDCHEM (2023)

Article Biochemistry & Molecular Biology

Investigating the promising SARS-CoV-2 main protease inhibitory activity of secoiridoids isolated from Jasminum humile; in silico and in virto assessments with structure-activity relationship

Ahmed A. Al-Karmalawy, Radwan Alnajjar, Ayman Abo Elmaaty, Faizah A. Binjubair, Sara T. Al-Rashood, Basma S. Mansour, Ahmed Elkamhawy, Wagdy M. Eldehna, Khaled Ahmed Mansour

Summary: This study found that seven compounds isolated from Jasminum humile showed inhibitory activity against SARS-CoV-2 M-pro in vitro and in silico. The total extract (T1) exhibited the most significant activity, while the fractions (Fr1 and Fr3) also showed good activity. Molecular docking revealed that five of the compounds had high affinities towards the M-pro target.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS (2023)

Letter Oncology

Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3

Yanira Zeyn, Kristin Hausmann, Melisa Halilovic, Mandy Beyer, Hany S. Ibrahim, Walburgis Brenner, Siavosh Mahboobi, Matthias Bros, Wolfgang Sippl, Oliver H. Kraemer

LEUKEMIA (2023)

Article Chemistry, Multidisciplinary

Fragment merging approach for design, synthesis, and biological assessment of urea/acetyl hydrazide clubbed thienopyrimidine derivatives as GSK-3β inhibitors

Joseph S. Saleh, Soha R. Abd El Hadi, Hany S. Ibrahim, Eman Z. Elrazaz, Khaled A. M. Abouzid

Summary: New thienopyrimidine derivatives were designed and synthesized as GSK-3 beta inhibitors based on the structure of the active binding site of the enzyme. Compound 6b and 6a showed moderate inhibitory activity against GSK-3 beta. Molecular docking study and ADME prediction suggested that the synthesized compounds may have limited ability to penetrate the blood brain barrier, reducing the chances of CNS side effects, but may also lead to drug-drug interactions.

BMC CHEMISTRY (2023)

Article Chemistry, Multidisciplinary

Theophylline-based hybrids as acetylcholinesterase inhibitors endowed with anti-inflammatory activity: synthesis, bioevaluation, in silico and preliminary kinetic studies

Abdullah A. Elgazar, Ramadan A. El-Domany, Wagdy M. Eldehna, Farid A. Badria

Summary: In this study, the conjugation of theophylline with different natural compounds was investigated to develop new hybrids with dual activity against cholinergic and inflammatory pathways for the treatment of Alzheimer's disease. Two hybrids, acefylline-eugenol 6d and acefylline-isatin 19, showed potent inhibition of acetylcholinesterase (AChE) and significant anti-inflammatory effects. Molecular docking studies revealed their ability to interact with key targets involved in Alzheimer's disease. The compounds also demonstrated stability in simulated gastric and intestinal environments, indicating their potential for absorption into the bloodstream. These findings highlight the therapeutic potential of these hybrids and provide promising avenues for further development as treatments for Alzheimer's disease.

RSC ADVANCES (2023)

Article Chemistry, Medicinal

Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection

Shuang Mei, Su Jiang, Yuting Wang, Han Jing, Peng Yang, Miao-Miao Niu, Jindong Li, Kai Yuan, Yan Zhang

Summary: This study identifies a dual-targeting peptide, AP-1, that effectively inhibits variants of concern (VOCs) of SARS-CoV-2 without impairing host cell viability. The findings suggest that AP-1 could be a promising broad-spectrum agent for treating emerging VOCs of SARS-CoV-2.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of proteolysis-targeting chimera targeting undruggable proteins using a covalent ligand screening approach

Hyeonjun Lee, Ju Yeon Lee, Hyunsoo Jang, Hye Young Cho, Minhee Kang, Sang Hyun Bae, Suin Kim, Eunji Kim, Jaebong Jang, Jin Young Kim, Young Ho Jeon

Summary: By using liquid chromatography-tandem mass spectrometry and nuclear magnetic resonance experiments, we identified new chemical moieties that bind to the target sites of the protein of interest, allowing for reversible binding and protein degradation. This method has the potential to expand the application of PROTAC technology.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A pro-death autophagy-based nanoplatform for enhancing antitumour efficacy with improved immune responses

Yingying Li, Xiyou Du, Xinru Kong, Yuelin Fang, Zhijing He, Dongzhu Liu, Hang Wu, Jianbo Ji, Xiaoye Yang, Lei Ye, Guangxi Zhai

Summary: This study proposes a novel nanoplatform based on the autophagy cascade to overcome the obstacles in chemo-immunotherapy. The platform combines chemotherapy and starvation therapy to initiate pro-death autophagy and enhance antigen presentation, while also remodeling the immunosuppressive tumor microenvironment. Furthermore, the study discovers a new therapeutic direction for the respiration inhibitor 3-bromopyruvic acid (3BP) in cancer treatment. Overall, this study offers an opportunity to improve antitumor efficacy and boost immune responses.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

A novel scaffold long-acting selective estrogen receptor antagonist and degrader with superior preclinical profile against ER plus breast cancer

Bingsi Wang, Mingxu Ma, Yusen Dai, Pengfei Yu, Liang Ye, Wenyan Wang, Chunjie Sha, Huijie Yang, Yingjie Yang, Yunjing Zhu, Lin Dong, Shujuan Wei, Linlin Wang, Jingwei Tian, Hongbo Wang

Summary: Breast cancer is a common malignant tumor in women, and drug resistance remains a clinical challenge. In this study, a novel compound, G-5b, was developed with potent antagonistic and degradation activities comparable to the current drug fulvestrant. G-5b also showed improved stability and solubility. Mechanistically, G-5b engages the proteasome pathway to degrade ER, inhibiting the ER signaling pathway and inducing apoptosis and cell cycle arrest. In animal models, G-5b exhibited superior pharmacokinetics and pharmacodynamics properties. Overall, G-5b is a promising long-acting SERD worthy of further investigation and optimization.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents

Karoline B. Waitman, Larissa C. de Almeida, Marina C. Primi, Jorge A. E. G. Carlos, Claudia Ruiz, Thales Kronenberger, Stefan Laufer, Marcia Ines Goettert, Antti Poso, Sandra V. Vassiliades, Vinicius A. M. de Souza, Monica F. Z. J. Toledo, Neuza M. A. Hassimotto, Michael D. Cameron, Thomas D. Bannister, Leticia Costa-Lotufo, Joa o A. Machado-Neto, Mauricio T. Tavares, Roberto Parise-Filho

Summary: A series of hybrid inhibitors combining pharmacophores of known kinase inhibitors and benzohydroxamate HDAC inhibitors were synthesized and evaluated for their anticancer activity and pharmacokinetic properties. Compounds 4d-f exhibited promising cytotoxicity against hematological cells and moderate activity against solid tumor models. Compound 4d showed potent inhibition of multiple kinase targets and had stable interactions with HDAC and members of the JAK family. These compounds showed selective cytotoxicity with minimal effects on non-tumorigenic cells and favorable pharmacokinetic profiles.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Unexpected rearrangement of ivermectin in the synthesis of new derivatives with trypanocidal and antiplasmodial activities

Michal Sulik, Diana Fontinha, Dietmar Steverding, Szymon Sobczak, Michal Antoszczak, Miguel Prudencio, Adam Huczynski

Summary: This study describes the synthesis of the first-in-class ivermectin derivatives obtained through derivatization of the C13 position, along with the unexpected rearrangement of the macrolide ring. These derivatives show potential for antiparasitic activity and are important for the development of new antiparasitic agents.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Novel ligustilide derivatives target quorum sensing system LasR/LasB and relieve inflammatory response against Pseudomonas aeruginosa infection

Jun Liu, Qiu-Xian Chen, Wen-Fu Wu, Dong Wang, Si -Yu Zhao, Jia-Hao Li, Yi-Qun Chang, Shao-Gao Zeng, Jia-Yi Hu, Yu-Jie Li, Jia-Xin Du, Shu-Meng Jiao, Hai-Chuan Xiao, Qiang Zhang, Jun Xu, Jian-Fu Zhao, Hai -Bo Zhou, Yong-Heng Wang, Jian Zou, Ping-Hua Sun

Summary: A new anti-infective drug strategy has been discovered to attenuate virulence and modulate inflammation caused by drug-resistant Pseudomonas aeruginosa infections. Compound 5f inhibits biofilm formation, macrophage migration, and inflammatory response induced by P. aeruginosa, showing potential as a novel candidate against drug-resistant infections.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Design and synthesis of pterostilbene derivatives bearing triazole moiety that might treat DSS-induced colitis in mice through modulation of NF-KB/ MAPK signaling pathways

Liuzeng Chen, Ke Wang, Lingyun Wang, Wei Wang, Lifan Wang, Jia Li, Xiaohan Liu, Mengya Wang, Banfeng Ruan

Summary: In this study, a series of novel anti-inflammatory compounds were designed and synthesized based on the natural product pterostilbene skeleton. Among them, compound 8 showed the highest activity and exhibited its effects through inhibition of pro-inflammatory cytokines by blocking the NF-KB/MAPK signaling pathway. Compound 8 also demonstrated a good relieving effect on acute colitis in mice and showed good safety in acute toxicity experiments.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)

Article Chemistry, Medicinal

Discovery of 4-(N-dithiobenzyl piperazine)-1,8-naphthalimide as a potent multi-target antitumor agent with good efficacy, limited toxicity, and low resistance

Si-Min Liang, Gui-Bin Liang, Hui-Ling Wang, Hong Jiang, Xian-Li Ma, Jian-Hua Wei, Ri-Zhen Huang, Ye Zhang

Summary: A series of novel multi-target antitumor agents were designed, synthesized, and evaluated. Some compounds exhibited significant antitumor activity and one compound showed excellent efficacy, limited toxicity, and low resistance. Further mechanism studies revealed that the compound exerted antitumor effects through multiple pathways.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2024)